ANI Pharmaceuticals Inc
Research ANI Pharmaceuticals Inc (ANIP) on Bullrun: valuation model: 2.5% undervalued, market cap USD 1.91B, P/E 21.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANIP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal2.5% undervalued
- Market capUSD 1.91B
- P/E21.3
- Financial periodFY2025
- RevenueUSD 883.37M
- Revenue growth43.8%
- Net incomeUSD 78.00M
- Free cash flowUSD 171.39M
Valuation Snapshot
Bullrun's latest valuation model marks ANI Pharmaceuticals Inc as 2.5% undervalued; latest market cap is USD 1.91B; P/E is 21.3.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
Frequently asked questions
Is ANI Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks ANI Pharmaceuticals Inc as 2.5% undervalued.
What is ANI Pharmaceuticals Inc's market cap?
ANI Pharmaceuticals Inc's market capitalization is USD 1.91B.
What is ANI Pharmaceuticals Inc's P/E ratio?
ANI Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 21.3.
What does ANI Pharmaceuticals Inc do?
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.